Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04609280 · ClinicalTrials.gov registry record · Phase 2
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
A Phase 2 study of Head and Neck Cancer and Oropharynx Cancer, sponsored by University of Maryland, Baltimore.
- Active
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 6
- Study locations
NCT04609280: Active Phase 2 study of Head and Neck Cancer and Oropharynx Cancer, sponsored by University of Maryland, Baltimore.
NCT04609280 is a Phase 2 study of Head and Neck Cancer and Oropharynx Cancer that is active but no longer recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 52 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (80% lower). The trial reports 6 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04609280, a Phase 2 study of Head and Neck Cancer and Oropharynx Cancer, is active but no longer recruiting, sponsored by University of Maryland, Baltimore.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a phase II, non-randomized, therapeutic trial with the primary objective to determine the efficacy of reduced contralateral (C/L) elective nodal treatment volumes in preventing C/L recurrences at 2 years in patients with p16 positive oropharyngeal squamous cell carcinoma undergoing definitive or adjuvant RT.
Primary Outcome
Time to failure will be calculated from the date of informed consent until the date of nodal failure in the untreated elective neck sub-volume.
Conditions Studied
Interventions
- RADIATION Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)
Study Locations (6)
Maryland
- Maryland Proton Treatment Center - Baltimore
- UMMC - Baltimore
- University of Maryland Greenebaum Cancer Center - Baltimore
- Upper Chesapeake Health - Bel Air
- Central Maryland Radiation Oncology - Columbia
- Baltimore Washington Medical Center - Glen Burnie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What the registry record for NCT04609280 still lists
NCT04609280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (80% lower).
The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT) is the first listed.
NCT04609280 lists 6 locations in 1 state (Maryland).
Frequently Asked Questions
What is clinical trial NCT04609280 about?
NCT04609280 is a clinical study titled "Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)". This is a phase II, non-randomized, therapeutic trial with the primary objective to determine the efficacy of reduced contralateral (C/L) elective nodal treatment volumes in preventing C/L recurrences at 2 years in patients with p16 positive oropharyngeal squamous cell carcinoma undergoing definitiv...
What is the current status of trial NCT04609280?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2021-03-01. Estimated completion is 2027-12.
What conditions does trial NCT04609280 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Oropharynx Cancer, Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04609280?
The interventions under investigation include: Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT) (RADIATION).
Who is sponsoring clinical trial NCT04609280?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04609280 being conducted?
This trial has 6 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04609280's enrollment target sits among peer trials
52 127th of 250 higher than 122 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI